Last reviewed · How we verify
NCT05547373: IPC-HAI
Infection Prevention and Control Intervention to Reduce Hospital-acquired Infections
NA trial testing Infection prevention and control (IPC) in Hospital-acquired Infections in 192 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | National University of Singapore |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 192 |
| Start date | 1 April 2023 |
| Primary completion | 30 June 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Cambodia |
Drugs / interventions tested
- Infection prevention and control (IPC)
Conditions studied
- Hospital-acquired Infections — all drugs for Hospital-acquired Infections →
Sponsor
National University of Singapore
Who can join
18 and older, any sex, with Hospital-acquired Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hospital-acquired infections (HAIs) are significant public health issues, especially in low- and middle-income countries (LMICs). Hand hygiene and low-level disinfection of equipment (LLDE) practices among healthcare workers (HCWs) are essential to reduce HAIs. Various effective infection prevention and control (IPC) interventions to reduce HAI incidence have been developed. However, which interventions work effectively in LMICs has not been identified. The investigators aim to develop, pilot, and assess the feasibility and acceptability of an IPC intervention in Cambodia and the Lao People's Democratic Republic (PDR).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Developing an infection prevention and control intervention to reduce hospital-acquired infections in Cambodia and Lao People's Democratic Republic: the HAI-PC study protocol.
Oy S, Saing CH, Ung M, Zahari M, et al · · 2023 · cited 5× · PMID 37799162 · DOI 10.3389/fpubh.2023.1239228
Verify or expand the search:
- PubMed search for NCT05547373
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National University of Singapore trials
Trials by the same sponsor.
- NCT07519642 — Frailty Improvement Through Technology With Informal Caregiver Supported Exercise (FITWISE) for Pre-frail and Frail Comm · NA · not yet recruiting
- NCT07525492 — Die-logue Program for Community Dwelling Adults: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07375459 — Community-based Mobile-assisted Brief Intervention for Smoking Cessation · NA · recruiting
- NCT07444073 — Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock · not yet recruiting
- NCT07282041 — Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05547373 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National University of Singapore
- Last refreshed: 14 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05547373.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing